Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:4:7-11.
doi: 10.2147/CPAA.S25784. Epub 2012 Feb 17.

Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid

Justin John Gandy  1 , Johanna Petronella Meeding, Jacques René Snyman, Constance Elizabeth Jansen van Rensburg
Affiliations

Phase 1 clinical study of the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid

Justin John Gandy et al. Clin Pharmacol. 2012.

Abstract

Background: The purpose of this research was to determine the acute and subacute safety and proof-of-concept efficacy of carbohydrate-derived fulvic acid (CHD-FA).

Methods: In this double-blind study, 30 male volunteers with predetermined atopy were randomly assigned to either Group A or Group B, each consisting of 15 participants. In part 1 of the study, the groups were administered increasing amounts of CHD-FA, ranging from 5 mL to 40 mL, provided that no adverse events had occurred at the previous dosage. In part 2, Group A participants received 20 mL of 3.8% CHD-FA twice daily for 3 days and were monitored for a week. Because no adverse events occurred, Group B received 40 mL of 3.8% CHD-FA twice daily for a period of 3 days. In part 3, both groups received either 40 mL of 3.8% CHD-FA or placebo twice daily for a period of one week, followed by a one-week washout period before crossover to the alternative treatment schedule. Parameters used to establish safety were electrocardiography, a physical examination, a health questionnaire, and hematology and biochemistry, determined at baseline, during regular calculated intervals, and at the end of each part of the study. A skin prick test was done as part of the screening process and, from the result, the allergen the participant was most allergic to was then selected, along with the positive histamine and negative control to be repeated at the start and end of each respective stage.

Results: Safety parameters remained constant throughout the trial. A significant decrease in skin prick test results was observed.

Conclusion: No severe adverse events occurred, establishing that CHD-FA to be safe at doses up to 40 mL twice daily for a week and that at this dosage CHD-FA acts as an anti-inflammatory agent. These findings confirm earlier animal data.

Keywords: CHD-FA; anti-inflammatory; efficacy; safety.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Liver function tests. Abbreviations: ALT, alanine transaminase; AST, aspartate transminase; Alk Phos, alkaline phosphatase; Gamma GT, gamma glutamyl transpeptidase.
Figure 2
Figure 2
Kidney function tests.
Figure 3
Figure 3
Kidney function tests.
Figure 4
Figure 4
Side effects reported on CHD-FA. Abbreviations: bid, twice daily; CHD-F, carbohydrate-derived fulvic acid.
See this image and copyright information in PMC

References

    1. Hayes MHB, MacCarthy P, Malcom RL, Swift RS. The search for structure: setting the scene. In: Hayes MHB, MacCarthy P, Malcom RL, Swift RS, editors. Humic Substances II Search of Structure. Chichester, UK: John Wiley and Sons; 1989.
    1. Sparks DL. Environmental Soil Chemistry. New York, NY: Academic Press; 2003.
    1. Van Rensburg CEJ, Malfeld SCK, Dekker J. Topical application of oxifulvic acid suppresses the cutaneous immune response in mice. Drug Dev Res. 2001;53:29–32.
    1. Snyman JR, Dekker J, Malfeld SCK, van Rensburg CEJ. Pilot study to evaluate the safety and therapeutic efficacy of topical oxifulvic acid in atopic volunteer. Drug Dev Res. 2002;57:4043.
    1. Dekker J, Medlen CE. Fulvic acid and its use in the treatment of various conditions. PTC/IB/9901649 Patent Corporation Application. 1999